Akebia Therapeutics, Inc. (AKBA)
NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
At close: 04:00PM EDT
After hours:
| Previous close | 1.3700 |
| Open | 1.4100 |
| Bid | 1.4800 x 1700 |
| Ask | 1.5400 x 800 |
| Day's range | 1.4000 - 1.5000 |
| 52-week range | 0.7800 - 2.4800 |
| Volume | |
| Avg. volume | 5,044,431 |
| Market cap | 312.297M |
| Beta (5Y monthly) | 0.84 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Simply Wall St.
When Can We Expect A Profit From Akebia Therapeutics, Inc. (NASDAQ:AKBA)?
With the business potentially at an important milestone, we thought we'd take a closer look at Akebia Therapeutics...
- Zacks
Akebia (AKBA) Up as Vafseo Gets FDA Nod for Anemia Due to CKD
Akebia (AKBA) gains during premarket hours on Mar 28 as its key product Vafseo (vadadustat) tablets receive FDA's approval for the treatment of anemia due to chronic kidney disease.
- Barrons.com
Akebia Awaits FDA Word On Second Crack At Vadadustat
The FDA, which turned away Akebia's initial application last March 2022, has a target action of Wednesday on the company's resubmission, which included safety data from tens of thousands of patients in Japan, where vadadustat was approved in mid-2020. Akebia has said it is prepping for a U.S. commercial launch of vadadustat in the second half if it gets an FDA green light.
© 2024 Yahoo. All rights reserved.